New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
16:08 EDTHPTXHyperion says EMA to review of marketing authorization application for RAVICTI
Hyperion Therapeutics announced that the European Medicines Agency has completed technical and content validation and accepted the filing of the Marketing Authorisation Application for RAVICTI Oral Liquid for the treatment of urea cycle disorders. Acceptance of the MAA confirms that the submission is complete so as to permit a substantive review by the Rapporteurs and the Committee for Medicinal Products for Human Use. "We are very pleased to receive MAA acceptance for review of RAVICTI and anticipate a CHMP opinion in the third quarter of 2015," said Hyperion CEO Donald Santel.
News For HPTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 24, 2014
05:45 EDTHPTXHyperion Therapeutics to host analyst day
Analyst day to be held on September 30 at 9 am. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use